This database contains 30 studies, archived under the term: "tolerability"
Click here to filter this large number of results.
Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer’s disease with neuropsychiatric features: a randomised, double-blind, exploratory trial
Yancheva, S.,
Ihl, R.,
Nikolova, G.,
Panayotov, P.,
Schlaefke, S.,
Hoerr, R.
Objective: This randomised, double-blind exploratory trial was undertaken to compare treatment effects and tolerability of EGb 761(R), donepezil and combined treatment in patients with AD and neuropsychiatric features.; Method: We enrolled 96 outpatients, aged 50 years or above, who met the NINCDS/ADRDA criteria for probable AD, scored below 36 on the TE4D, a screening test […]
Rosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: results from a randomized, double-blind, placebo-controlled phase III study
Gold, Michael,
Alderton, Claire,
Zvartau-Hind, Marina,
Egginton, Sally,
Saunders, Ann M.,
Irizarry, Michael,
Craft, Suzanne,
Landreth, Gary,
Linnamägi, Ulla,
Sawchak, Sharon
Background/aims: A phase II study of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone extended release (RSG XR) in mild-to-moderate Alzheimer’s disease (AD) detected a treatment benefit to cognition in apolipoprotein E(APOE)-ε4-negative subjects. The current phase III study with prospective stratification by APOE genotype was conducted to confirm the efficacy and safety of RSG XR in mild-to-moderate […]
Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study
Doody, Rachelle S.,
Ferris, Steven,
Salloway, Stephen,
Yijun, Sun,
Goldman, Robert,
Yikang, Xu,
Gao, Jeff,
Murthy, Anita K.
Following a 48-week, double-blind, randomized, placebo-controlled trial of donepezil in 821 patients with amnestic mild cognitive impairment (aMCI), safety and tolerability of donepezil (10 mg) were further evaluated in a 28-week extension study. Of 499 participants who completed the double-blind phase, 145 enrolled in the open-label study. Adverse events (AEs) were recorded throughout. Overall, 57.4% […]
A randomized, placebo-controlled trial of latrepirdine in Huntington disease
Kieburtz, Karl,
McDermott, Michael P.,
Voss, Tiffini S.,
Corey-Bloom, Jody,
Deuel, Lisa M.,
Dorsey, E. Ray,
Factor, Stewart,
Geschwind, Michael D.,
Hodgeman, Karen,
Kayson, Elise,
Noonberg, Sarah,
Pourfar, Michael,
Rabinowitz, Karen,
Ravina, Bernard,
Sanchez-Ramos, Juan,
Seely, Lynn,
Walker, Francis,
Feigin, Andrew
Objectives: To evaluate the safety and tolerability of latrepirdine in Huntington disease (HD) and explore its effects on cognition, behavior, and motor symptoms.; Design: Double-blind, randomized, placebo-controlled trial.; Setting: Multicenter outpatient trial.; Participants: Ninety-one participants with mild to moderate HD enrolled at 17 US and UK centers from July 18, 2007, through July 16, 2008.; […]
Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease
Galasko, D.,
Bell, J.,
Mancuso, J. Y.,
Kupiec, J. W.,
Sabbagh, M. N.,
van Dyck, C.,
Thomas, R. G.,
Aisen, P. S.
Objective: To examine safety, tolerability, and efficacy of PF-04494700, an inhibitor of the receptor for advanced glycation end products (RAGE), in mild to moderate Alzheimer disease (AD).; Methods: Double-blind, placebo-controlled trial at 40 academic centers (United States). Subjects with AD and Mini-Mental State Examination score 14-26 were randomized to PF-04494700 60 mg/day × 6 days, […]
Oxytocin for frontotemporal dementia: A randomized dose-finding study of safety and tolerability
Finger, E. C.,
MacKinley, J.,
Blair, M.,
Oliver, L. D.,
Jesso, S.,
Tartaglia, M. C.,
Borrie, M.,
Wells, J.,
Dziobek, I.,
Pasternak, S.,
Mitchell, D. G. V.,
Rankin, K.,
Kertesz, A.,
Boxer, A.
Objective: To determine the safety and tolerability of 3 doses of intranasal oxytocin (Syntocinon; Novartis, Bern, Switzerland) administered to patients with frontotemporal dementia (FTD). Methods: We conducted a randomized, parallel-group, double-blind, placebo-controlled study using a dose-escalation design to test 3 clinically feasible doses of intranasal oxytocin (24, 48, or 72 IU) administered twice daily for […]
Treatment of Alzheimer’s disease with the GSK-3 inhibitor tideglusib: a pilot study
del Ser, Teodoro,
Steinwachs, Klaus C.,
Gertz, Hermann J.,
Andrés, María V.,
Gómez-Carrillo, Belén,
Medina, Miguel,
Vericat, Joan A.,
Redondo, Pilar,
Fleet, David,
Leon, Teresa
This pilot, double-blind, placebo-controlled, randomized, escalating dose trial explored the safety and efficacy of tideglusib, an inhibitor of glycogen synthase kinase-3, in Alzheimer’s disease (AD) patients. Thirty mild-moderate AD patients on cholinesterase inhibitor treatment were administered escalating doses (400, 600, 800, 1,000 mg) of tideglusib or placebo (ratio 2 : 1) for 4, 4, 6, […]
Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer’s disease: a multicenter, randomized, open-label, parallel-group study
Choi, Seong Hye,
Park, Kyung Won,
Na, Duk L.,
Han, Hyun Jeong,
Kim, Eun-Joo,
Shim, Yong S.,
Lee, Jae-Hong,
The EXPECT Study Group,
Objective: To compare the tolerability and efficacy of combination therapy of memantine plus rivastigmine patch with rivastigmine patch monotherapy in patients with mild to moderate Alzheimer’s disease (AD).; Research Design and Methods: In this multicenter, randomized, open-label study, patients entered an 8-week run-in period (a 5 cm 2 rivastigmine patch for 4 weeks, then a […]